Canada NHP labelling changes: what to update now and what can wait
A practical label planning guide for brands balancing regulatory changes, packaging inventory and the cost of redesigning twice.
Request an NHP label reviewWhat should a brand do first?
Start by separating safety-directed changes, existing compliance gaps and monograph-related updates. Health Canada has announced flexibility for certain monograph updates and plans to propose a transition beyond June 2028. The replacement timeline is not yet final. Use the extra planning space to audit your labels and control artwork changes.[1][2]
Who this is for: Canadian NHP licence holders, international brands entering Canada, private-label businesses and teams managing several packaging versions.
What is changing, and what is still proposed?
The May 2026 bulletin identifies June 21, 2028 as the current compliance date for the 2022 labelling amendments. It signals further amendments, targeted for consultation in spring 2027, with a proposed transition extending beyond that date. A planned extension is different from a finalized replacement deadline.[2]
Which label changes should you address now?
The October bulletin provides administrative flexibility for monograph-related label updates. It excludes safety changes required by a Health Canada notice, request or direction. Do not use it as a blanket reason to leave every label issue unresolved. The table below is a practical triage framework, not a substitute for reading the notice applicable to your product.[1]
| Situation | Practical response | Record to keep |
|---|---|---|
| Health Canada directs a safety update | Follow the specified deadline and assess affected stock. | Notice, implementation plan and completion evidence. |
| Artwork differs from the authorized product | Assess the discrepancy and the appropriate correction or submission. | Licence-to-label comparison and regulatory decision. |
| Update arises from a revised monograph | Assess eligibility for the interim approach and document the plan. | Monograph version, change summary and rationale. |
| Redesign is mainly for the coming format changes | Build a flexible layout; review proposals before a large print commitment. | Artwork assumptions and decision checkpoint. |
| Commercial rebrand or new pack size | Combine planned changes after a technical review. | Approved master copy and version history. |
How to audit an NHP label before redesigning it
Build a master copy document before asking a designer to adjust a crowded panel. Include the product identity, ingredient declarations, directions, risk information and required business details. Compare that master against the licence and the applicable labelling requirements, then compare the actual artwork against the master. This makes missing text and inconsistent versions much easier to identify.
For bilingual packs, review both languages as one controlled record. A late translation can change line breaks, panel space and the readability of warnings. Review the smallest marketed pack first because it usually reveals the toughest layout constraints.[3]
Review the label as a complete product record.
The bottle, carton, online listing and approved licence should tell a consistent story. A bilingual review is most useful when it happens alongside the technical assessment, before design decisions become expensive.
How to avoid paying for two packaging overhauls
Create a SKU register that connects each artwork version to its remaining stock, print quantity and next production run. A low-volume SKU with a large label inventory may need a different purchasing decision from a fast-moving product that will be reprinted next month. Keep regulatory due dates separate from commercial preferences in the register.
Before ordering a long packaging run, ask what information could change before those labels are used. Consider a smaller order, a flexible carton layout or coordinated artwork work where commercially sensible. Any approach involving existing stock still needs a product-specific compliance assessment; unused inventory alone does not justify continued use of an incorrect label.
Worked planning example: one brand, three different decisions
Imagine a brand with a capsule product receiving a safety-directed update, a powder affected by a routine monograph revision and a third product scheduled for a visual rebrand. Treating all three as one redesign project could delay the urgent change or create unnecessary rework.
Our suggested approach is to give the safety change its own implementation track, assess the powder against the interim bulletin and hold the rebrand’s final print approval until its technical copy is settled. Assign a decision owner and a review date for each. This is an illustrative planning example, not a statement that any particular product qualifies for deferral.
What should a useful label review deliver?
A useful review leaves the brand with instructions that a designer can implement: marked-up artwork, approved wording, a list of unresolved questions and a version-controlled decision log. It should distinguish required corrections from optional editorial improvements.
Ask for a clear handoff between the regulatory reviewer, translator, designer and person approving the print proof. Record who checks the final file after changes are made. A technically correct comment has little value if the wrong artwork revision reaches the printer.
What to gather before requesting a review
Send what you have and identify what is still being developed. These documents help us define a useful scope and the questions to resolve first.
- Current product licence and any amendments
- Marketed label PDFs for every bottle, carton and pack size
- Proposed artwork and English/French copy
- Relevant monographs and any Health Canada correspondence
- Inventory quantities, print lead times and planned production dates
- Marketplace listings and other consumer-facing claims
Questions brands ask
Has the June 2028 deadline already been replaced?
A later transition is planned for proposed amendments. Do not assume a specific replacement date until the regulatory process establishes it. Check the latest Health Canada bulletin before making a print decision.
Can we defer a safety warning change?
The interim monograph flexibility does not cover safety changes directed by Health Canada. Follow the timeline in the applicable notice or direction.
Should we stop all label redesign work?
No. Complete your licence-to-label audit, master copy and inventory planning now. Separate those useful tasks from final print decisions that depend on future requirements.
Can a designer alone complete the review?
Design expertise helps with layout and readability. Technical copy, licence alignment and regulatory decisions also need appropriate review. Define those responsibilities before artwork begins.
Can Kompete review one product or a full catalogue?
The scope can be organized around a single SKU or a portfolio. Share the labels, licences and intended changes so the review can be scoped around the decisions you need.
Turn the next decision into a clear plan.
Kompete can review your current artwork, identify the reason for each proposed change and prepare a prioritized action list for regulatory and design teams.
Request an NHP label reviewExplore this serviceinfo@kompeteconsulting.com
Related insights
Sources and scope
Sources checked October 22, 2026. Regulatory requirements and guidance can change. The checklists, examples and development workflows are Kompete’s practical planning suggestions; product-specific decisions require review of the actual formula, intended use and documentation.